<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paricalcitol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paricalcitol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Paricalcitol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10197" href="/d/html/10197.html" rel="external">see "Paricalcitol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11993" href="/d/html/11993.html" rel="external">see "Paricalcitol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F206463"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zemplar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867844"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zemplar</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1029635"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Vitamin D Analog</span>;</li>
<li>
<span class="list-set-name">Vitamin, Fat Soluble</span></li></ul></div>
<div class="block dop drugH1Div" id="F206476"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> KDIGO guidelines suggest that in children vitamin D analogs may be considered to maintain serum calcium levels in an age-appropriate normal range, which differs from recommendation in adult patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="48abb9ef-27ea-43fd-a829-f999bf4f7850">Secondary hyperparathyroidism associated with stage 5 chronic renal failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary</b>
<b> hyperparathyroidism associated with stage 5 chronic renal failure (CKD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents ≤16 years:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial dose:</i> Calculate based on intact parathyroid hormone (iPTH) serum levels using the following equation. Round the calculated dose <b>down</b> to the nearest whole number and administer calculated dose 3 times/week and no more frequently than every other day.</p>
<p style="text-indent:-2em;margin-left:10em;">Initial dose (mcg) = baseline iPTH (pg/ml) divided by 120.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Titration:</i> Every 4 weeks, may increase dose by 1 mcg/dose (eg, increase from 1 mcg 3 times/week to 2 mcg 3 times/week) to maintain iPTH within target range. Based on response and clinical markers (iPTH, serum Ca, and P), each administered dose may be decreased 2 mcg/dose at any time. If dosage reduction is required while receiving 1 or 2 mcg 3 times/week, discontinue therapy and resume when appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥17 years: <b>Note: </b>To reduce the risk of hypercalcemia, initiate only after baseline serum calcium has been adjusted to ≤9.5 mg/dL. In patients where laboratory markers are monitored less frequently than once weekly, more modest dosing should be used.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial dose:</i> Calculate based on iPTH serum levels using the following equation and administer calculated dose 3 times/week and no more frequently than every other day.</p>
<p style="text-indent:-2em;margin-left:10em;">Initial dose (mcg) = baseline iPTH (pg/mL) divided by 80.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Titration</i>
<i>: </i>Adjust mcg dose based on at least weekly labs (iPTH, Ca, and P); administer calculated dose 3 times/week and not more often than every other day.</p>
<p style="text-indent:-2em;margin-left:10em;">iPTH level (pg/mL) based: Dose (mcg) = Most recent iPTH level (pg/mL) divided by 80.</p>
<p style="text-indent:-2em;margin-left:10em;">Elevated serum calcium: Decrease dose by 2 to 4 mcg.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>For modest dosing adjustments: </i>In situations where monitoring of iPTH, calcium, and phosphorus occurs less frequently than once per week, a more modest initial and dose titration rate may be warranted. Calculate based on iPTH serum levels using the following equation and administer calculated dose 3 times/week and no more frequently than every other day.</p>
<p style="text-indent:-2em;margin-left:10em;">Modest dose (mcg) = Most recent iPTH level (pg/mL) divided by 100.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral: Children ≥5 years and Adolescents: IV through HD access (not directly into vein):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial: </i>Dose based on baseline serum iPTH; administer 3 times weekly at any time during dialysis session, and no more frequently than every other day:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i></i>iPTH &lt;500 pg/mL: 0.04 mcg/kg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">iPTH ≥500 pg/mL: 0.08 mcg/kg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosing adjustment:</i> Prior to any paricalcitol dosing adjustments, ensure serum Ca is within normal limits. The dose of paricalcitol should be adjusted based on iPTH levels relative to baseline and targets as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">Above target and iPTH level decreased by &lt;30%: Increase paricalcitol dose by 0.04 mcg/kg/dose every 2 to 4 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">iPTH level ≥150 pg/mL and decreased by ≥30% to ≤60%: Maintain current paricalcitol dose.</p>
<p style="text-indent:-2em;margin-left:8em;">iPTH level &lt;150 pg/mL <b>or</b> decreased by &gt;60%: Decrease weekly paricalcitol dose by 0.04 mcg/kg or by 50% if decreased dose is zero.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1a2ca85-e321-4327-96e9-c41a05aa35f1">Secondary hyperparathyroidism associated with stage 3 and 4 chronic renal failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary hyperparathyroidism associated with stage 3 and 4 chronic renal failure (CKD<b>)</b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents ≤16 years: Oral: Initial: 1 mcg 3 times/week no more frequently than every other day; may titrate every 4 weeks; increase dose by 1 mcg (eg, increase from 1 mcg 3 times/week to 2 mcg 3 times/week) to maintain iPTH within target range. Based on response and clinical markers (iPTH, serum Ca, and P), each administered dose may be decreased by 1 mcg at any time. If dosage reduction is required while receiving 1 mcg 3 times/week, discontinue therapy, resuming when appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years: <b>Note:</b> If using 3 times/week dosing, doses should not be administered more frequently than every other day:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial: </i>Dose based on baseline serum iPTH: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">iPTH ≤500 pg/mL: 1 mcg once daily or 2 mcg 3 times/week.</p>
<p style="text-indent:-2em;margin-left:8em;">iPTH &gt;500 pg/mL: 2 mcg once daily or 4 mcg 3 times/week.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Titration and dosage adjustment: </i>May adjust at 2- to 4-week intervals based on iPTH level relative to baseline:</p>
<p style="text-indent:-2em;margin-left:8em;">iPTH same or increased: Increase paricalcitol dose <b>by</b> 1 mcg once daily or 2 mcg 3 times/week.</p>
<p style="text-indent:-2em;margin-left:8em;">iPTH decreased by &lt;30%: Increase paricalcitol dose <b>by</b> 1 mcg once daily or 2 mcg 3 times/week.</p>
<p style="text-indent:-2em;margin-left:8em;">iPTH decreased by ≥30% and ≤60%: Maintain paricalcitol dose.</p>
<p style="text-indent:-2em;margin-left:8em;">iPTH decreased by &gt;60%: Decrease paricalcitol dose <b>by </b>1 mcg/day or 2 mcg 3 times/week (see <b>Note</b>).</p>
<p style="text-indent:-2em;margin-left:8em;">iPTH &lt;60 pg/mL: Decrease paricalcitol dose <b>by</b> 1 mcg/day or 2 mcg 3 times/week (see <b>Note</b>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b> Note:</b> If patient is taking the lowest dose (1 mcg) on the daily regimen and an additional dose reduction is necessary, then regimen should be changed to 1 mcg 3 times weekly. If further reduction is required, withhold drug as needed and restart at a lower dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51196598"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: No adjustment necessary; paricalcitol indicated for use in chronic kidney disease stages 3 through 5.</p></div>
<div class="block dohp drugH1Div" id="F51152024"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adjustment not needed for mild-to-moderate impairment. Paricalcitol has not been evaluated in severe hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F206466"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10197" href="/d/html/10197.html" rel="external">see "Paricalcitol: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> KDIGO guidelines do not recommend routine use of vitamin D analogs in patients not on dialysis with chronic kidney disease (CKD) stages G3 to G5; it may be reasonable to reserve use for patients with CKD stages G4 or G5 and with severe and progressive hyperparathyroidism. Caution is advised to avoid hypercalcemia or elevated phosphate levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>). Do not initiate in patients with serum calcium at the ULN (eg, &gt;9.5 mg/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c8a2273-f5c3-4cf0-8f00-9f2c08e654d1">Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 0.04 to 0.1 mcg/kg (2.8 to 7 mcg) given no more frequently than every other day at any time during dialysis; adjust dose based on serum intact PTH (iPTH) goal of 2 to 9 times the ULN for the assay used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>), as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH above target and increased: Increase by 2 to 4 mcg every 2 to 4 weeks; maximum dose: 0.24 mcg/kg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH above target and decreased by &lt;30%: Increase by 2 to 4 mcg every 2 to 4 weeks; maximum dose: 0.24 mcg/kg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH above target and decreased by 30% to 60%: Maintain paricalcitol dose.</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH above target and decreased by &gt;60%: Decrease paricalcitol dose based on clinical judgement.</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH at target and stable: Maintain paricalcitol dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dose suspension may be necessary due to persistent and abnormally low iPTH (goal iPTH 2 to 9 times the ULN for the assay used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1'])">Ref</a></span>)) to reduce risk of adynamic bone disease or serum calcium persistently above normal; restart therapy at a reduced dose after iPTH and/or serum calcium has normalized.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Conversion to IV paricalcitol from IV calcitriol:</b> A conversion ratio of <b>paricalcitol to calcitriol</b> of approximately 3:1 or 4:1 may be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12631365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12631365'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial dose is calculated, in mcg, based on baseline iPTH level divided by 80 and administered 3 times weekly, no more frequently than every other day. <b>Note:</b> To reduce the risk of hypercalcemia initiate only after baseline serum calcium has been adjusted to ≤9.5 mg/dL.</p>
<p style="text-indent:-2em;margin-left:6em;">Dose titration:</p>
<p style="text-indent:-2em;margin-left:8em;">Titration dose (mcg) = Most recent iPTH level (pg/mL) divided by 80</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> In situations where monitoring of iPTH, calcium, and phosphorus occurs less frequently than once per week, a more modest initial and dose titration rate may be warranted:</p>
<p style="text-indent:-2em;margin-left:10em;">Modest titration dose (mcg) = Most recent iPTH level (pg/mL) divided by 100</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage adjustment for elevated serum calcium:</i> Decrease dose by 2 to 4 mcg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="849d7322-a852-41bc-80ea-95c9d28d9d2b">Secondary hyperparathyroidism associated with stage 3 and 4 CKD</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary hyperparathyroidism associated with stage 3 and 4 CKD:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial dose based on baseline serum iPTH:</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH ≤500 pg/mL: <b>Oral: </b>1 mcg once daily or 2 mcg 3 times/week.</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH &gt;500 pg/mL: <b>Oral: </b>2 mcg once daily or 4 mcg 3 times/week.</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">
<i>Dosage adjustment based on iPTH level relative to baseline</i>, adjust dose at 2- to 4-week intervals:</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH same or increased: <b>Oral: </b>Increase paricalcitol dose by 1 mcg once daily or 2 mcg 3 times/week.</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH decreased by &lt;30%: <b>Oral: </b>Increase paricalcitol dose by 1 mcg once daily or 2 mcg 3 times/week.</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH decreased by ≥30% and ≤60%: <b>Oral: </b>Maintain paricalcitol dose.</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH decreased by &gt;60%: <b>Oral: </b>Decrease paricalcitol dose by 1 mcg once daily* or 2 mcg 3 times/week.</p>
<p style="text-indent:-2em;margin-left:6em;">iPTH &lt;60 pg/mL: <b>Oral:</b> Decrease paricalcitol dose by 1 mcg once daily* or 2 mcg 3 times/week.</p>
<p style="text-indent:-2em;margin-left:6em;">*If patient is taking 1 mcg once daily and further dose reduction is needed, decrease to 1 mcg 3 times/week. If further dose reduction is required, withhold therapy as needed and restart at a lower dosing frequency.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991597"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50988801"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F206445"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported in adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (children, adolescents, and adults: 6% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (children and adolescents: 17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial flutter (&lt;2%), cardiac arrhythmia (&lt;2%), chest discomfort (&lt;2%), chest pain (≤3%), edema (6% to 7%), hypertension (≤7%), hypotension (≤5%), palpitations (3%), peripheral edema (3%), syncope (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (&lt;2%), alopecia (&lt;2%), burning sensation of skin (&lt;2%), dermal ulcer (3%), night sweats (&lt;2%), pruritic rash (&lt;2%), pruritus (&lt;2%), skin blister (&lt;2%), skin rash (4%), urticaria (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (3%), hirsutism (&lt;2%), hypercalcemia (&lt;2%), hyperkalemia (&lt;2%), hyperphosphatemia (&lt;2%), hypervolemia (5%), hypocalcemia (&lt;2%), hypoglycemia (3%), hypoparathyroidism (&lt;2%), increased thirst (&lt;2%), weight loss (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (≤4%), constipation (children, adolescents, and adults: ≤5%), decreased appetite (&lt;2%), diarrhea (≤7%), dysgeusia (&lt;2%), dysphagia (&lt;2%), gastritis (&lt;2%), gastroesophageal reflux disease (&lt;2%), gastrointestinal hemorrhage (5%), ischemic bowel disease (&lt;2%), peritonitis (5%), rectal hemorrhage (&lt;2%), vomiting (children, adolescents, and adults: ≤8%), xerostomia (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction (&lt;2%), malignant neoplasm of breast (&lt;2%), mastalgia (&lt;2%), urinary tract infection (3%), urinary urgency (children and adolescents: 6%), vaginal infection (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (&lt;2%), lymphadenopathy (&lt;2%), prolonged bleeding time (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (&lt;2%), increased serum aspartate aminotransferase (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (3%), infection (3%), sepsis (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (&lt;2%), agitation (&lt;2%), anxiety (3%), asthenia (&lt;2%), cerebrovascular accident (&lt;2%), chills (5%), confusion (&lt;2%), delirium (&lt;2%), depression (3%), dizziness (≤7%), fatigue (≤3%), headache (children, adolescents, and adults: ≤5%), hypoesthesia (&lt;2%), insomnia (≤5%), malaise (3%), myoclonus (&lt;2%), nervousness (&lt;2%), pain (&lt;2%), paresthesia (&lt;2%), restlessness (&lt;2%), unresponsive to stimuli (&lt;2%), vertigo (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (5%), arthritis (5%), back pain (3%), joint stiffness (&lt;2%), muscle spasm (3%), muscle twitching (&lt;2%), myalgia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (children and adolescents: 6%; adults: &lt;2%), glaucoma (&lt;2%), ocular hyperemia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Chronic renal failure (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (children and adolescents: 6%), cough (≤3%), dyspnea (&lt;2%), nasopharyngitis (≤8%), oropharyngeal pain (4%), orthopnea (&lt;2%), pneumonia (5%), pulmonary edema (&lt;2%), sinusitis (3%), upper respiratory tract infection (&lt;2%), wheezing (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (5%), swelling (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Abdominal pain (children and adolescents)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (including laryngeal edema)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine</p></div>
<div class="block coi drugH1Div" id="F206457"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to paricalcitol or any component of the formulation; vitamin D toxicity; hypercalcemia</p></div>
<div class="block war drugH1Div" id="F206442"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia, and adynamic bone disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercalcemia: Progressive and/or acute hypercalcemia may increase risk of cardiac arrhythmias and seizures; chronic hypercalcemia may lead to generalized vascular and other soft-tissue calcification, exacerbate nephrolithiasis, and has been associated with increased mortality in adults with chronic kidney disease (CKD) (KDIGO 2017). High intake of calcium and phosphate with vitamin D (and its derivatives) may increase risk of hypercalciuria and hyperphosphatemia. Risk of hypercalcemia may be increased by concomitant use of calcium-containing supplements, other vitamin D compounds, and/or medications that increase serum calcium (eg, thiazide diuretics). Monitor serum calcium frequently in high-risk patients.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878579"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F206452"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zemplar: 1 mcg, 2 mcg [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mcg, 2 mcg, 4 mcg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zemplar: 2 mcg/mL (1 mL); 5 mcg/mL (1 mL, 2 mL) [contains alcohol, usp, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mcg/mL (1 mL); 5 mcg/mL (1 mL, 2 mL)</p></div>
<div class="block geq drugH1Div" id="F206438"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422271"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Paricalcitol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mcg (per each): $8.00 - $11.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mcg (per each): $17.73 - $22.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mcg (per each): $24.53 - $44.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Zemplar Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mcg (per each): $15.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mcg (per each): $31.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Paricalcitol Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mcg/mL (per mL): $4.80 - $5.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mcg/mL (per mL): $12.00 - $14.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Zemplar Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mcg/mL (per mL): $7.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mcg/mL (per mL): $18.18</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867845"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zemplar: 1 mcg, 2 mcg, 4 mcg [contains alcohol, usp]</p></div>
<div class="block adip drugH1Div" id="F53568088"><span class="drugH1">Additional Information</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic kidney disease (CKD):</b> Children ≥2 years, Adolescents, and Adults: CKD is defined as GFR &lt;60 mL/minute/1.73 m<sup>2</sup> or kidney damage for &gt;3 months; GFR category, albuminuria category, and cause of kidney damage are used in conjunction to assign a stage (KDIGO 2012; KDIGO 2017):</p>
<p style="text-indent:-2em;margin-left:4em;">GFR categories:</p>
<p style="text-indent:-2em;margin-left:6em;">G1: Normal or increased GFR; GFR ≥90 mL/minute/1.73 m<sup>2 </sup>WITH kidney damage</p>
<p style="text-indent:-2em;margin-left:6em;">G2: Mild decrease in GFR; GFR 60 to 89 mL/minute/1.73 m<sup>2</sup> WITH kidney damage</p>
<p style="text-indent:-2em;margin-left:6em;">G3a: Mild to moderate decrease in GFR; GFR 45 to 59 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:6em;">G3b: Moderate to severe decrease in GFR; GFR 30 to 44 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:6em;">CKD G4: Severe decrease in GFR; GFR 15 to 29 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:6em;">CKD G5: Kidney failure; GFR &lt;15 mL/minute/1.73 m<sup>2</sup> or dialysis</p>
<p style="text-indent:-2em;margin-left:4em;">Albuminuria categories:</p>
<p style="text-indent:-2em;margin-left:6em;">A1: Normal or mildly increased</p>
<p style="text-indent:-2em;margin-left:6em;">A2: Moderately increased</p>
<p style="text-indent:-2em;margin-left:6em;">A3: Severely increased</p></div>
<div class="block admp drugH1Div" id="F52613527"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered with or without food. With the 3 times/week dosing schedule, doses should not be given more frequently than every other day.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Administer undiluted as an IV bolus through hemodialysis port at any time during dialysis. Doses should not be administered more often than every other day.</p></div>
<div class="block adm drugH1Div" id="F730141"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with or without food. With the 3 times/week dosing schedule, doses should not be given more frequently than every other day.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer as a bolus dose at any time during dialysis. May be administered through a hemodialysis vascular access port or intravenously if an access port is unavailable. Doses should not be administered more often than every other day.</p></div>
<div class="block sts drugH1Div" id="F10493725"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53568230"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) in patients on dialysis (FDA approved in ages ≥5 years and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Prevention and treatment of secondary hyperparathyroidism associated with stages 3 and 4 CKD and stage 5 CKD patients on hemodialysis or peritoneal dialysis (FDA approved in ages ≥10 years and adults)</p></div>
<div class="block mst drugH1Div" id="F7297725"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound alike/look alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Paricalcitol may be confused with calcifediol, calcitriol</p>
<p style="text-indent:-2em;margin-left:4em;">Zemplar may be confused with zaleplon, Zelapar, Zemuron, zolpidem, ZyPREXA Zydis</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F730134"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F206447"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.  Management: Consider avoiding chronic use of aluminum and aluminum-containing products in patients who are also taking active vitamin D analogs. If coadministered, monitor aluminum status and for signs and symptoms of aluminum-related toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg, cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Burosumab: Vitamin D Analogs may enhance the adverse/toxic effect of Burosumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Paricalcitol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Paricalcitol may enhance the adverse/toxic effect of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib.  Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the absorption of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or 2 hours after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.  Management: Consider avoiding chronic use of aluminum and aluminum-containing products, such as sucralfate, in patients who are also taking active vitamin D analogs. If combined, monitor for signs and symptoms of aluminum-related toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.<i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F730140"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain coconut or palm kernel oil.</p></div>
<div class="block pri drugH1Div" id="F730133"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53568207"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of vitamin D intoxication</p>
<p style="text-indent:-2em;margin-left:2em;">Serum calcium and phosphorus (closely monitor levels during dosage titration and after initiation of a strong CYP3A4 inhibitor):</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Twice weekly during initial phase, then at least monthly once dose established</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: At least every 2 weeks for 3 months or following dose adjustment, then monthly for 3 months, then every 3 months</p>
<p style="text-indent:-2em;margin-left:2em;">KDIGO 2017 guidelines: <b>Note:</b> Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">CKD</p></th>
<th align="center">
<p style="text-indent:0em;">Calcium</p></th>
<th align="center">
<p style="text-indent:0em;">Phosphorous</p></th>
<th align="center">
<p style="text-indent:0em;">Alkaline Phosphatase</p></th>
<th align="center">
<p style="text-indent:0em;">PTH</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">G2 to G3b</p></td>
<td align="center">
<p style="text-indent:0em;">Every 6 to 12 months</p></td>
<td align="center">
<p style="text-indent:0em;">Every 6 to 12 months</p></td>
<td align="center">
<p style="text-indent:0em;">Based on clinical condition</p></td>
<td align="center">
<p style="text-indent:0em;">Based on baseline and progression of disease</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">G4</p></td>
<td align="center">
<p style="text-indent:0em;">Every 3 to 6 months</p></td>
<td align="center">
<p style="text-indent:0em;">Every 3 to 6 months</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 months (more often in presence of elevated PTH)</p></td>
<td align="center">
<p style="text-indent:0em;">Every 6 to 12 months</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">G5 and G5d</p></td>
<td align="center">
<p style="text-indent:0em;">Every 1 to 3 months</p></td>
<td align="center">
<p style="text-indent:0em;">Every 1 to 3 months</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 months (more often in presence of elevated PTH)</p></td>
<td align="center">
<p style="text-indent:0em;">Every 3 to 6 months</p></td></tr></tbody></table>
</div>
<div class="block rerp drugH1Div" id="F53568058"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Due to the complexity and interdependency of the laboratory parameters used for therapeutic decisions in chronic kidney disease-mineral and bone disorder (CKD-MBD) patients, serial assessments of phosphate, calcium, and intact parathyroid hormone (iPTH) levels should be considered together (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">PTH:</p>
<p style="text-indent:-2em;margin-left:4em;">CKD stage G3a to G5: Optimal PTH level is unknown; evaluate patients with progressively elevated intact PTH levels or if levels are consistently above the normal range (assay-dependent) (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">Dialysis patients: Maintain iPTH within 2 to 9 times the upper limit of normal for the assay used (KDIGO 2017).</p></div>
<div class="block pha drugH1Div" id="F206441"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Decreased renal conversion of vitamin D to its primary active metabolite (1,25-hydroxyvitamin D) in chronic renal failure leads to reduced activation of vitamin D receptor (VDR), which subsequently removes inhibitory suppression of parathyroid hormone (PTH) release; increased serum PTH (secondary hyperparathyroidism) reduces calcium excretion and enhances bone resorption. Paricalcitol is a synthetic vitamin D analog which binds to and activates the VDR in kidney, parathyroid gland, intestine and bone, thus reducing PTH levels and improving calcium and phosphate homeostasis.</p></div>
<div class="block phk drugH1Div" id="F206456"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Healthy subjects: Oral: 34 L; IV: 24 L </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stage 3 and 4 CKD: Oral: 44 to 46 L</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Stage 5 CKD: Oral: 38 to 49 L; IV: 31 to 35 L </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: &gt;99%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hydroxylation and glucuronidation via hepatic and nonhepatic enzymes, including CYP24, CYP3A4, UGT1A4; forms metabolites (at least one active) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral: 72% to 86% in healthy subjects</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;">Healthy subjects: Oral: 4 to 6 hours; IV: 5 to 7 hours </p>
<p style="text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;">Stage 3 and 4 CKD: Oral: 17 to 20 hours</p>
<p style="text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;">Stage 5 CKD (on HD or PD): Oral: 14 to 18 hours; IV: 14 to 15 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: 3 hours: Delayed by food</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Healthy subjects: Feces (oral: 70%; IV: 63%); urine (oral: 18%, IV: 19%); 51% to 59% as metabolites</p></div>
<div class="block phksp drugH1Div" id="F51192055"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Compared with healthy subjects, chronic kidney disease subjects on dialysis showed a decreased clearance and increased half-life.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F206458"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Biocalcitol | Palikalex | Paricalcitol Sandoz | Paritol | Zemplar</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Paricalcitol accord | Paricalcitol fresenius | Paricalcitol hospira | Paricalmed | Zemplar</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Paricon</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Paratol | Tevaparivit | Zemplar</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Paricalcitol accord | Paricalcitol agmed | Paricalcitol fresenius | Paricalcitol hospira | Paricalcitol rafarm | Paricalcitol teva | Rextol | Rikalpa | Zemplar</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Paricalcitol accord | Paricalcitol normon | Paricalcitol ratiopharm | Paricalcitol sun | Pasonican | Zemplar</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Paricalcitol accordpharma | Paricalcitol apotex | Paricalcitol Combino Pharm | Paricalcitol ges | Paricalcitol normon | Paricalcitol stada | Paricalcitol sun | Paricalcitol teva | Paricalcitol vir | Zemplar</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Paricalcitol accord | Paricalcitol Alternova | Paricalcitol hospira | Zemplar</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aricitol | Paricalcitol/hospira | Paricalcitol/teva | Rextol | Viapinal | Zemplar | Zilidor</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Paricalcitol fresenius | Zemplar</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Paracalcitolo accord | Paracalcitolo sandoz | Paracalcitolo sun | Paracalcitolo teva | Zemplar</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pacitol | Zemplar</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Paricalcitol accord | Paricalcitol eureco pharma | Zemplar</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Paricalcitol Alternova | Zemplar</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Paricalcitol fresenius</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Paricalcit accord | Paricalcitol fresenius | Paricalcitol hospira | Paricalcitol normon | Zemplar</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Paricalcitol 2care4 | Paricalcitol accord | Paricalcitol Alternova | Parikalcitol ebb | Zemplar</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Calsipar | Deparic | Paksitu | Parical | Paricaver | Parigen | Pariquel | Paritolin | Rechrositol | Zemplar | Zemsitol</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Zemplar</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Paricalcitol normon | Zemplar</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17533024">
<a name="17533024"></a>Greenbaum LA, Benador N, Goldstein SL, et al, "Intravenous Paricalcitol for Treatment of Secondary Hyperparathyroidism in Children on Hemodialysis," <i>Am J Kidney Dis</i>, 2007, 49(6):814-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/17533024/pubmed" id="17533024" target="_blank">17533024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDOQI.1">
<a name="KDOQI.1"></a>K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. <i>Am J Kidney Dis</i>. 2005;46(4)(suppl 1):S1-S121.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDOQI.2">
<a name="KDOQI.2"></a>K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 1. Evaluation of calcium and phosphorus metabolism. <i>Am J Kidney Dis</i>. 2003;42(4)(suppl 3):52-57.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDOQI.3">
<a name="KDOQI.3"></a>K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Guideline 3. Evaluation of serum phosphorus levels. <i>Am J Kidney Dis</i>. 2003;42(4)(suppl 3):62-63.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDOQI.4">
<a name="KDOQI.4"></a>K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Part 4. Definition and Classification of Stages of Chronic Kidney Disease. <i>Am J Kidney Dis</i>. 2002;39(2)(suppl 1):46-75.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19644521">
<a name="19644521"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). <i>Kidney Int Suppl</i>. 2009;(113):S1-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/19644521/pubmed" id="19644521" target="_blank">19644521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). <i>Kidney Int</i>. 2017;7(suppl 1):1-59. doi:10.1016/j.kisu.2017.04.001</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2">
<a name="KDIGO.2"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. <i>Kidney Int Suppl</i>. 2013;(3):1-150.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14580225">
<a name="14580225"></a>Sanchez CP. Secondary Hyperparathyroidism in Children With Chronic Renal Failure: Pathogenesis and Treatment. <i>Paediatr Drugs</i>. 2003;5(11): 763-776.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/14580225/pubmed" id="14580225" target="_blank">14580225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16900383">
<a name="16900383"></a>Seeherunvong W, Nwobi, O, Abitbol CL, et al. Paricalcitol Versus Calcitriol Treatment for Hyperparathyroidism in Pediatric Hemodialysis Patients. <i>Pediatr Nephrol</i>. 2006;21(10):1434-1439.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/16900383/pubmed" id="16900383" target="_blank">16900383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12631365">
<a name="12631365"></a>Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. <i>Kidney Int</i>. 2003;63(4):1483-1490. doi:10.1046/j.1523-1755.2003.00878.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/12631365/pubmed" id="12631365" target="_blank">12631365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zemplar.1">
<a name="Zemplar.1"></a>Zemplar (paricalcitol) capsules [prescribing information]. North Chicago, IL: AbbVie Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zemplar.2">
<a name="Zemplar.2"></a>Zemplar (paricalcitol) injection [prescribing information]. North Chicago, IL; AbbVie Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16898852">
<a name="16898852"></a>Ziolkowska H. Minimizing Bone Abnormalities in Children With Renal Failure. <i>Paediatr Drugs</i>. 2006;8(4):205-222.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/paricalcitol-pediatric-drug-information/abstract-text/16898852/pubmed" id="16898852" target="_blank">16898852</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13032 Version 245.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
